DEB for Symptomatic Intracranial Atherosclerosis Stenosis

Not Applicable

Active, not recruiting

• Conditions: Cerebral Ischemia; Cerebral Atherosclerosis
• Interventions: Device: Drug eluting balloon (Vmoky)

• Registration Number: NCT04821726
• Lead Sponsor: Yinyi(Liaoning) Biotech Co., Ltd.

Brief Summary

A prospective, multi-center, single-arm study to evaluate the safety and efficacy of drug eluting balloon catheter for the treatment of patients with symptomatic intracranial atherosclerotic stenosis.

Detailed Description

This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of drug eluting balloon catheter (Vmoky) produced by Yinyi (Liaoning) Biotech Co., Ltd. for the treatment of patients with symptomatic intracranial atherosclerotic stenosis.

Study Timeline

• Study First Submitted: 2021-03-14
• Study First Submitted QC: 2021-03-26
• Study First Posted: 2021-03-29
• Study Start: 2021-06-21
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-28
• Last Update Posted: 2023-01-31
• Primary Completion: 2023-08-30
• Study Completion: 2023-11-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 155

Inclusion Criteria

1. Age 18 to 80 years old；
2. Symptomatic intracranial artery stenosis, the degree of intracranial diseased artery vascular stenosis measured under cerebral angiography between 70~99% (WASID method)；
3. Symptoms are still recurrent after conservative medication (symptoms refer to stroke and transient ischemic episodes of the brain)，or intracranial artery stenosis combined with remote low perfusion performance (rCBF or rCBV abnormalities) in patients.
4. The stenotic vessels are located in the internal carotid artery (intracranial segment), middle cerebral artery, vertebral artery (intracranial segment), basilar artery, distal blood vessels are normal；
5. Only one lesion needed to be treated；
6. The intracranial artery needed to be treated l art mm in diameter；
7. Pre-expansion must be satisfied: forward blood flow TICI 3 level, pre-expanded guide wire retention, observation for 5 minutes, residual stenosis is still ≤50%; without blood limited dissection；
8. Patients have at least 1 porridge plaque risk factor, including past or existing hypertension, diabetes, hyperlipidemia, smoking;
9. mRS≤3 points；
10. Patients or their guardians are able to understand the purpose of the trial, voluntarily participate in and sign a written informed consent form, and receive follow-up visits from patients.

Exclusion Criteria

1. Target lesion is in-stent restenosis；
2. Exist lesion stenosis more than 50% out of the target vessel；
3. Intracranial haemorrhage occurred within 3 months (substantial cerebral hemorrhage, large amount of subcranial hemorrhage, subdural/external bleeding)；
4. Acute ischemic stroke has occurred in the last two weeks；
5. Stenosis caused by non-atherosclerosis: e.g. arterial mezzanine, moya-moya disease, vasculitis, radioactive vascular disease or fibrous muscle dysplasia;
6. Severe calcified, angulate and Mori type C lesions, as well as congenital development of thin blood vessels and fenestration；
7. Combine intracranial tumors, aneurysms, or intracranial venous malformations；
8. There are risk factors that can lead to cardiogenic embolism: fibrillation, left-ventricle thrombosis, mycardial infarction within 6 weeks, etc；
9. Uncontrollable hypertension by medication (Systolic pressure≥ystolic pres diastolic blood pressure≥pressurec；
10. Severe combined or unstable conditions, such as severe heart failure, lung failure or kidney failure (serum creatinine>3.0mg/dL (264 μmol/L) or renal cyspheric filtration rate (GFR) <30ml/min), severe liver insequencies, malignant tumors;
11. A history of gastrointestinal haemorrhage or haemorrhagic disease (e.g. idiopathic platelet reduction cyanosis, etc.) or a history of bleeding tendencies within 6 months prior to the signing of the informed consent；
12. Hemoglobin is below 90g/L, plateplates<90×109/L；
13. The International Standardized Rate (INR) >1.5, with unreal corrective bleeding factors；
14. Can not carry out antiplatelet/anticoagulant treatment, with anaesthetic and contrast agent contraindication;
15. The angiography shows that the vascular path is curly, and the device is difficult to reach the target position or to withdraw；
16. Patients known to be allergic to heparin, paclitaxel, contrast, aspirin and clopidogrel, anesthetics;
17. Life expectancy is less than 1 year；
18. Participants in other drug or device clinical trials that have not been completed；
19. A pregnant or lactating woman, or a person planning to become pregnant within one year；
20. Other conditions that the researchers consider patients are not suitable.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Drug eluting balloon (Vmoky)	Drug eluting balloon (Vmoky)	A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.

Primary Outcome Measures

Name	Time	Method
Restenosis	6 months (+60 days)	Restenosis was defined as greater than 50% stenosis within or immediately adjacent (within 5 mm) to the implanted balloon(s) or stent(s) and greater than 20% absolute luminal loss.

Secondary Outcome Measures

Name	Time	Method
The success rate of device	immediately after procedure	device successfully cross the lesion and inflate, post-procedural residual stenosis no more than 50%, no use of bail-out stent
Target lesion stenosis	6 months (+60 days) and 12 months (±60 days)	Calculate the stenosis degree with Quantitative Coronary Angiography (QCA) method
Restenosis	12 months (±60 days)	Restenosis was defined as greater than 50% stenosis within or immediately adjacent (within 5 mm) to the implanted balloon(s) or stent(s) and greater than 20% absolute luminal loss.
Ischemic stroke and transient ischemic attack (TIA) out of the area of the responsible blood vessels	30 days (±7 days), 6 months (±60 days), 12 months (±60 days)	Number of participants that occur these events
Stroke events	30 days (±7 days), 6 months (±60 days) and 12 months (±60 days)	Number of participants that occur these events
Ischemic stroke and transient ischemic attack (TIA) in the area of the responsible blood vessels	30 days (±7 days), 6 months (±60 days) and 12 months (±60 days)	Number of participants that occur these events
Angiographic success rate	immediately after procedure	TICI 3 blood flow, residual stenosis no more than 50% after 5 minutes and no flow-limited dissection
The success rate of procedure	In-hospital (Maximum 7 days after procedure)	Base on the device success, there is no stroke or death in-hospital
Non-stroke bleeding	12 months (±60 days)	Number of participants that occur this event
Mortality	30 days (±7 days), 6 months (±60 days) and 12 months (±60 days)	Number of participants that occur this event
Serious adverse events and adverse events	12 months (±60 days)	Number of participants that occur these events

Trial Locations

Locations (1)

Henan Provincial People's Hospital; 🇨🇳 Zhengzhou, Henan, China